UK Markets close in 37 mins

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
157.74-3.29 (-2.04%)
As of 10:53AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close161.03
Bid156.78 x 1000
Ask156.91 x 900
Day's range155.31 - 159.67
52-week range117.08 - 464.00
Avg. volume1,283,976
Market cap38.255B
Beta (5Y monthly)-0.70
PE ratio (TTM)5.00
EPS (TTM)31.54
Earnings date09 Nov 2021
Forward dividend & yield2.11 (1.33%)
Ex-dividend date02 Jun 2022
1y target est320.42
  • Motley Fool

    This May Be Pfizer's Key to Long-Term Vaccine Dominance

    Pfizer (NYSE: PFE) is already the leader in the coronavirus vaccine space. Rival Moderna (NASDAQ: MRNA) has a significant position in the market. Latecomer Novavax (NASDAQ: NVAX) could also take market share in the months to come.

  • The Telegraph

    German drugmaker accused of stealing Covid vaccine technology

    The team behind Britain’s most-used Covid booster vaccine is being sued by a German pharmaceutical firm which has accused it of stealing the technology behind the jab.

  • Reuters

    CureVac files patent lawsuit in Germany against BioNTech over mRNA technology

    BERLIN (Reuters) -CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus. The German-based biotech company is seeking "fair compensation" from BioNTech and two subsidiaries for infringement of its intellectual property rights, it said on Tuesday. When asked in a media call, Chief Executive Franz-Werner Haas did not rule out further legal action against BioNTech partner Pfizer or mRNA vaccine maker Moderna.